.jpg){kind=link}
How it started
History
Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Steven Squinto and Leonard Bell, a physician at Yale New Haven Hospital and assistant professor of medicine and pathology at Yale School of Medicine.
In 2000, Alexion moved its headquarters from New Haven to Cheshire, Connecticut.
Alexion received U.S. Food and Drug Administration (FDA) approval for Soliris in 2007. It was initially approved to treat paroxysmal nocturnal hemoglobinuria, a rare blood disorder.
In June 2010, there was an outbreak of hemolytic–uremic syndrome caused by shigatoxigenic and verotoxigenic Escherichia coli (EHEC) in Germany. Soliris was tested as a treatment option because of its effectiveness in treating atypical hemolytic uremic syndrome, an illness similar to that caused by the EHEC infection.
In January 2014, the company paid Moderna $100 million for ten product options to develop rare disease treatments, including for Crigler–Najjar syndrome, using Moderna's mRNA therapeutics platform; however, the program was scrapped in January 2017 after animal trials showed that Moderna's treatment would never be safe enough for humans.
From Wikipedia’s article on Alexion Pharmaceuticals, shared under CC BY-SA 4.0.3